Skip to main content

ASCO Meeting 2023

Ph 1b/II study of QL1706 or QL1604 plus bevacizumab as first-line in advanced hepatocellular carcinoma

QL1706(PSB205) – Abstract 4077

RETURN TO PRESENTATIONS